Arcus Biosciences Inc
NYSE:RCUS

  • LAST PRICE
    15.3800
  • TODAY'S CHANGE (%)
    -0.0100 (-0.0650%)
  • Bid / Lots
    15.3700/ 2
  • Ask / Lots
    15.4000/ 2
  • Open / Previous Close
    15.6900 / 15.3900
  • Day Range
    15.3650
    15.7300
  • 52 Week Range
    12.9500
    20.3100
  • Volume
    94,011

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Sep 24, 2024

      Show headlines and story abstract

    • 4:35PM ET on Tuesday Sep 24, 2024 by Dow Jones
      Companies Mentioned: RCUS

      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted five new employees options to purchase a total of 38,600 shares of the Company's common stock at an exercise price per share of $15.71, which was the closing price on September 23, 2024, and restricted stock units to acquire a total of 19,300 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

  • Sep 10, 2024

      Show headlines and story abstract

    • 4:35PM ET on Tuesday Sep 10, 2024 by Dow Jones
      Companies Mentioned: RCUS
      HAYWARD, Calif.--(BUSINESS WIRE)--September 10, 2024--
      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 27,800 shares of the Company's common stock at an exercise price per share of $16.31, which was the closing price on September 9, 2024, and restricted stock units to acquire a total of 13,900 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

Peers Headlines